Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 26;6:102. doi: 10.1038/s42003-023-04485-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Schematic representation of the experiment with zabadinostat. Balb/c mice were treated with orally administrated zabadinostat at 25 mg/kg for 14 days (5 days on/2 days off) or vehicle only; n = 4 per group; b relative body weight representation of treated and non-treated mice; n = 4; results presented as mean values +/−SD. c General T-cell activation and CD4-positive T cells measured by flow cytometry; measurements were performed in pooled splenocytes from four mice; also, we noticed similar percentage of CD8-positive T cells in control and zabadinostat-treated groups (26.2% and 24.3%). The viability of the splenocytes was similar in zabadinostat treatment compare to untreated control (70.9% and 76.6% viable cells, respectively). d Analysis of panel of Th1, Th2, Th1/Th2, General Th, Th17 and Th9 cytokines in serum collected from mice treated with zabadinostat and the control group; n = 4; results presented as mean values +/−SD; Student’s t test.